{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T08:23:48Z","timestamp":1785572628412,"version":"3.56.0"},"reference-count":49,"publisher":"American Academy of Pediatrics (AAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,4,1]]},"abstract":"<jats:p>Background and Objective. Evidence suggests that synthetic surfactants consisting solely of phospholipids can be improved through the addition of peptides, such as sinapultide, that mimic the action of human surfactant protein-B (SP-B). A synthetic surfactant containing a mimic of SP-B may also reduce the potential risks associated with the use of animal-derived products. Our objective was to compare the efficacy and safety of a novel synthetic surfactant containing a functional SP-B mimic (lucinactant; Discovery Laboratories, Doylestown, PA) with those of a non\u2013protein-containing synthetic surfactant (colfosceril palmitate; GlaxoSmithKline, Brentford, United Kingdom) and a bovine-derived surfactant (beractant; Abbott Laboratories, Abbott Park, IL) in the prevention of neonatal respiratory distress syndrome (RDS) and RDS-related death.<\/jats:p><jats:p>Methods. We assigned randomly (double-masked) 1294 very preterm infants, weighing 600 to 1250 g and of \u226432 weeks gestational age, to receive colfosceril palmitate (n = 509), lucinactant (n = 527), or beractant (n = 258) within 20 to 30 minutes after birth. Primary outcome measures were the rates of RDS at 24 hours and the rates of death related to RDS during the first 14 days after birth. All-cause mortality rates, bronchopulmonary dysplasia (BPD) rates, and rates of other complications of prematurity were prespecified secondary outcomes. Primary outcomes, air leaks, and causes of death were assigned by an independent, masked, adjudication committee with prespecified definitions. The study was monitored by an independent data safety monitoring board.<\/jats:p><jats:p>Results. Lucinactant reduced significantly the incidence of RDS at 24 hours, compared with colfosceril (39.1% vs 47.2%; odds ratio [OR]: 0.68; 95% confidence interval [CI]: 0.52\u20130.89). There was no significant difference in comparison with beractant (33.3%). However, lucinactant reduced significantly RDS-related mortality rates by 14 days of life, compared with both colfosceril (4.7% vs 9.4%; OR: 0.43; 95% CI: 0.25\u20130.73) and beractant (10.5%; OR: 0.35; 95% CI: 0.18\u20130.66). In addition, BPD at 36 weeks postmenstrual age was significantly less common with lucinactant than with colfosceril (40.2% vs 45.0%; OR: 0.75; 95% CI: 0.56\u20130.99), and the all-cause mortality rate at 36 weeks postmenstrual age was lower with lucinactant than with beractant (21% vs 26%; OR: 0.67; 95% CI: 0.45\u20131.00).<\/jats:p><jats:p>Conclusions. Lucinactant is a more effective surfactant preparation than colfosceril palmitate for the prevention of RDS. In addition, lucinactant reduces the incidence of BPD, compared with colfosceril palmitate, and decreases RDS-related mortality rates, compared with beractant. Therefore, we conclude that lucinactant, the first of a new class of surfactants containing a functional protein analog of SP-B, is an effective therapeutic option for preterm infants at risk for RDS.<\/jats:p>","DOI":"10.1542\/peds.2004-2183","type":"journal-article","created":{"date-parts":[[2005,4,1]],"date-time":"2005-04-01T18:03:40Z","timestamp":1112378620000},"page":"1018-1029","source":"Crossref","is-referenced-by-count":153,"title":["A Multicenter, Randomized, Masked, Comparison Trial of Lucinactant, Colfosceril Palmitate, and Beractant for the Prevention of Respiratory Distress Syndrome Among Very Preterm Infants"],"prefix":"10.1542","volume":"115","author":[{"given":"Fernando R.","family":"Moya","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of Texas Health Science Center at Houston, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janusz","family":"Gadzinowski","sequence":"additional","affiliation":[{"name":"University of Medical Sciences, Poznan, Poland, and Polish Mother's Memorial Hospital Research Institute, Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Bancalari","sequence":"additional","affiliation":[{"name":"Jackson Memorial Hospital, University of Miami, Miami, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Salinas","sequence":"additional","affiliation":[{"name":"National Institute of Perinatology, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Kopelman","sequence":"additional","affiliation":[{"name":"Hospital Sa\u0303o Paulo, University of Sao Paulo, Paulista School of Medicine, Sao Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Bancalari","sequence":"additional","affiliation":[{"name":"Regional Clinical Hospital Guillermo Grant-Benavente, University of Concepcio\u0301n, Concepcio\u0301n, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Katarzyna","family":"Kornacka","sequence":"additional","affiliation":[{"name":"Neonatology Clinic, Warsaw Medical University, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Allen","family":"Merritt","sequence":"additional","affiliation":[{"name":"St Charles Medical Center, Bend, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Segal","sequence":"additional","affiliation":[{"name":"Discovery Laboratories, Doylestown, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Schaber","sequence":"additional","affiliation":[{"name":"Discovery Laboratories, Doylestown, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huei","family":"Tsai","sequence":"additional","affiliation":[{"name":"Discovery Laboratories, Doylestown, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Massaro","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"d'Agostino","sequence":"additional","affiliation":[{"name":"Statistics and Consulting Unit, Department of Mathematics and Statistics, Boston University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the International Surfaxin Collaborative Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2005,4,1]]},"reference":[{"key":"2021120819313445800_R1","doi-asserted-by":"crossref","unstructured":"Avery ME, Mead J. Surface properties in relation to atelectasis with hyaline membrane disease. Am J Dis Child.\u20081959;97:517\u2013523","DOI":"10.1001\/archpedi.1959.02070010519001"},{"key":"2021120819313445800_R2","doi-asserted-by":"crossref","unstructured":"Soll RF. Prophylactic synthetic surfactant for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev.\u20082000;(2):CD001079","DOI":"10.1002\/14651858.CD000510"},{"key":"2021120819313445800_R3","doi-asserted-by":"crossref","unstructured":"Soll RF, Blanco F. Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. Cochrane Database Syst Rev.\u20082001;(2):CD000144","DOI":"10.1002\/14651858.CD000144"},{"key":"2021120819313445800_R4","doi-asserted-by":"crossref","unstructured":"Ainsworth SB, Milligan DW. Surfactant therapy for respiratory distress syndrome in premature neonates: a comparative review. Am J Respir Med.\u20082002;1:417\u2013433","DOI":"10.1007\/BF03257169"},{"key":"2021120819313445800_R5","unstructured":"Merritt TA, Strayer DS, Hallman M, Spragg RD, Wozniak P. Immunologic consequences of exogenous surfactant administration. Semin Perinatol.\u20081988;12:221\u2013230"},{"key":"2021120819313445800_R6","doi-asserted-by":"crossref","unstructured":"Strayer DS, Hallman M, Merritt TA. Immunogenicity of surfactant. II. Porcine and bovine surfactants. Clin Exp Immunol.\u20081991;83:41\u201346","DOI":"10.1111\/j.1365-2249.1991.tb05585.x"},{"key":"2021120819313445800_R7","doi-asserted-by":"crossref","unstructured":"Moya F, Hoffman D, Zhao B, Johnston JM. Platelet activating factor in surfactant preparations. Lancet.\u20081993;341:858\u2013860","DOI":"10.1016\/0140-6736(93)93062-6"},{"key":"2021120819313445800_R8","doi-asserted-by":"crossref","unstructured":"Erpenbeck VJ, Hagenberg A, Dulkys Y, et al. Natural porcine surfactant augments airway inflammation after allergen challenge in patients with asthma. Am J Respir Crit Care Med.\u20082004;169:578\u2013586","DOI":"10.1164\/rccm.200301-104OC"},{"key":"2021120819313445800_R9","doi-asserted-by":"crossref","unstructured":"Christie PE, Henderson WR Jr. Lipid inflammatory mediators: leukotrienes, prostaglandins, platelet-activating factor. Clin Allergy Immunol.\u20082002;16:233\u2013254","DOI":"10.1201\/9780429134432-12"},{"key":"2021120819313445800_R10","doi-asserted-by":"crossref","unstructured":"Whitsett JA, Hull WM, Luse S. Failure to detect surfactant protein-specific antibodies in sera of premature infants treated with Survanta, a modified bovine surfactant. Pediatrics.\u20081991;81:505\u2013510","DOI":"10.1542\/peds.87.4.505"},{"key":"2021120819313445800_R11","doi-asserted-by":"crossref","unstructured":"Chida S, Phelps DS, Soll RF, Taeusch HW. Surfactant proteins and anti-surfactant antibodies in sera from infants with respiratory distress syndrome with and without surfactant treatment. Pediatrics.\u20081991;88:84\u201389","DOI":"10.1542\/peds.88.1.84"},{"key":"2021120819313445800_R12","doi-asserted-by":"crossref","unstructured":"Hamvas A, Nogee LM, Mallory GB Jr, et al. Lung transplantation for treatment of infants with surfactant protein B deficiency. J Pediatr.\u20081997;130:231\u2013239","DOI":"10.1016\/S0022-3476(97)70348-2"},{"key":"2021120819313445800_R13","doi-asserted-by":"crossref","unstructured":"Kobayashi T, Robertson B, Grossmann G, Nitta K, Curstedt T, Suzuki Y. Exogenous porcine surfactant (Curosurf) is inactivated by monoclonal antibody to the surfactant-associated hydrophobic protein SP-B. Acta Paediatr.\u20081992;81:665\u2013671","DOI":"10.1111\/j.1651-2227.1992.tb12329.x"},{"key":"2021120819313445800_R14","unstructured":"Suzuki Y, Robertson B, Fujita Y, Grossmann G, Kogishi K, Curstedt T. Lung protein leakage in respiratory failure induced by a hybridoma making monoclonal antibody to the hydrophobic surfactant-associated polypeptide SP-B. Int J Exp Pathol.\u20081992;73:325\u2013333"},{"key":"2021120819313445800_R15","doi-asserted-by":"crossref","unstructured":"Robertson B, Kobayashi T, Ganzuka M, Grossmann G, Li WZ, Suzuki Y. Experimental neonatal respiratory failure induced by a monoclonal antibody to the hydrophobic surfactant-associated protein SP-B. Pediatr Res.\u20081991;30:239\u2013243","DOI":"10.1203\/00006450-199109000-00007"},{"key":"2021120819313445800_R16","doi-asserted-by":"crossref","unstructured":"Curstedt T, Jornvall H, Robertson B, et al. Two hydrophobic, low-molecular mass protein fractions of pulmonary surfactant: characterization and biophysical activity. Eur J Biochem.\u20081987;168:255\u2013262","DOI":"10.1111\/j.1432-1033.1987.tb13414.x"},{"key":"2021120819313445800_R17","doi-asserted-by":"crossref","unstructured":"Nogee LM, de Mello DE, Dehner LP, Colten HR. Deficiency of pulmonary surfactant protein B in congenital alveolar proteinosis. N Engl J Med.\u20081993;328:406\u2013410","DOI":"10.1056\/NEJM199302113280606"},{"key":"2021120819313445800_R18","doi-asserted-by":"crossref","unstructured":"Cole FS, Hamvas A, Nogee LM. Genetic disorders of neonatal respiratory function. Pediatr Res.\u20082001;50:157\u2013162","DOI":"10.1203\/00006450-200108000-00001"},{"key":"2021120819313445800_R19","doi-asserted-by":"crossref","unstructured":"Cochrane CG, Revak SD. Pulmonary surfactant protein B (SP-B): structure-function relationships. Science.\u20081991;254:566\u2013568","DOI":"10.1126\/science.1948032"},{"key":"2021120819313445800_R20","doi-asserted-by":"crossref","unstructured":"Nilsson G, Gustafsson M, Vandenbussche G, et al. Synthetic peptide-containing surfactants: evaluation of transmembrane versus amphipathic helices and surfactant protein C poly-valyl to poly-leucyl substitution. Eur J Biochem.\u20081998;255:116\u2013124","DOI":"10.1046\/j.1432-1327.1998.2550116.x"},{"key":"2021120819313445800_R21","doi-asserted-by":"crossref","unstructured":"Gustafsson M, Vandenbussche G, Curstedt T, Ruysschaert JM, Johansson J. The 21-residue surfactant peptide (LysLeu4)4Lys (KL4) is a transmembrane \u03b1-helix with a mixed nonpolar\/polar surface. FEBS Lett.\u20081996;384:185\u2013188","DOI":"10.1016\/0014-5793(96)00290-6"},{"key":"2021120819313445800_R22","doi-asserted-by":"crossref","unstructured":"Cochrane CG. Surfactant protein B and mimic peptides in the function of pulmonary surfactant. FEBS Lett.\u20081998;430:424","DOI":"10.1016\/S0014-5793(98)00710-8"},{"key":"2021120819313445800_R23","doi-asserted-by":"crossref","unstructured":"Manalo E, Merritt TA, Kheiter A, Amirkhanian J, Cochrane C. Comparative effects of some serum components and proteolytic products of fibrinogen on surface tension-lowering abilities of beractant and a synthetic peptide containing surfactant KL4. Pediatr Res.\u20081996;39:947\u2013952","DOI":"10.1203\/00006450-199606000-00004"},{"key":"2021120819313445800_R24","doi-asserted-by":"crossref","unstructured":"Andersson S, Kheiter A, Merritt TA. Oxidative inactivation of surfactants. Lung.\u20081999;177:179\u2013189","DOI":"10.1007\/PL00007639"},{"key":"2021120819313445800_R25","unstructured":"Nutt M, Patel N, Rairkar M, Niven RW. Comparison of the novel lung surfactant Surfaxin (lucinactant) with currently available commercial products. Pediatr Res.\u20082004;55:514A"},{"key":"2021120819313445800_R26","doi-asserted-by":"crossref","unstructured":"Cochrane CG, Revak SD, Merritt TA, et al. The efficacy and safety of KL4 surfactant in preterm infants with respiratory distress syndrome. Am J Respir Crit Care Med.\u20081996;153:404\u2013410","DOI":"10.1164\/ajrccm.153.1.8542150"},{"key":"2021120819313445800_R27","doi-asserted-by":"crossref","unstructured":"Cochrane CG, Revak SD. Pulmonary surfactant protein B (SP-B): structure-function relationships. Science.\u20081991;254:566\u2013568","DOI":"10.1126\/science.1948032"},{"key":"2021120819313445800_R28","unstructured":"GlaxoSmithKline. Exosurf neonatal (colfosceril palmitate) for intratracheal suspension [package insert]. Brentford, United Kingdom: GlaxoSmithKline; 1990"},{"key":"2021120819313445800_R29","unstructured":"Abbott Laboratories. Survanta (beractant) for intratracheal suspension [package insert]. Abbott Park, IL: Abbott Laboratories; 1999"},{"key":"2021120819313445800_R30","doi-asserted-by":"crossref","unstructured":"Hudak ML, Martin DJ, Egan EA, et al. A multicenter, randomized, masked, comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. Pediatrics.\u20081997;100:39\u201350","DOI":"10.1542\/peds.100.1.39"},{"key":"2021120819313445800_R31","doi-asserted-by":"crossref","unstructured":"Willson D. Calfactant. Expert Opin Pharmacother.\u20082001;2:1479\u20131493","DOI":"10.1517\/14656566.2.9.1479"},{"key":"2021120819313445800_R32","unstructured":"Vermont-Oxford Neonatal Network: A multicenter, randomized trial comparing synthetic surfactant versus modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome. Pediatrics.\u20081996;97:1\u20136"},{"key":"2021120819313445800_R33","doi-asserted-by":"crossref","unstructured":"Horbar JD, Wright LL, Soll RF, et al. A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. J Pediatr.\u20081993;123:757\u2013766","DOI":"10.1016\/S0022-3476(05)80856-X"},{"key":"2021120819313445800_R34","doi-asserted-by":"crossref","unstructured":"Wang Z, Baatz JE, Holm BA, Notter RH. Content-dependent activity of lung surfactant protein B in mixtures with lipids. Am J Physiol Lung Cell Mol Physiol.\u20082002;28:L897\u2013L906","DOI":"10.1152\/ajplung.00431.2001"},{"key":"2021120819313445800_R35","doi-asserted-by":"crossref","unstructured":"Notter, RH, Wang Z, Egan EA, Holm BA. Component-specific surface and physiological activity in bovine-derived lung surfactants. Chem Phys Lipids.\u20082002;114:21\u201334","DOI":"10.1016\/S0009-3084(01)00197-9"},{"key":"2021120819313445800_R36","doi-asserted-by":"crossref","unstructured":"Veldhuizen EJ, Diemel RV, Putz G, van Golde LM, Batenburg JJ, Haagsman HP. Effect of the hydrophobic surfactant proteins on the surface activity of spread films in the captive bubble surfactometer. Chem Phys Lipids.\u20082001;110:47\u201355","DOI":"10.1016\/S0009-3084(00)00228-0"},{"key":"2021120819313445800_R37","doi-asserted-by":"crossref","unstructured":"Beresford MW, Shaw NJ. Bronchoalveolar lavage surfactant protein A, B, and D concentrations in preterm infants ventilated for respiratory distress syndrome receiving natural and synthetic surfactants. Pediatr Res.\u20082003;53:663\u2013670","DOI":"10.1203\/01.PDR.0000054653.89527.F8"},{"key":"2021120819313445800_R38","doi-asserted-by":"crossref","unstructured":"Clark JC, Wert SE, Bachurski CJ, et al. Targeted disruption of the surfactant protein B gene disrupts surfactant homeostasis, causing respiratory failure in newborn mice. Proc Natl Acad Sci USA.\u20081995;92:7794\u20137798","DOI":"10.1073\/pnas.92.17.7794"},{"key":"2021120819313445800_R39","doi-asserted-by":"crossref","unstructured":"Revak SD, Merritt TA, Cochrane CG, et al. Efficacy of synthetic peptide-containing surfactant in the treatment of respiratory distress syndrome in preterm infant rhesus monkeys. Pediatr Res.\u20081996;39:715\u2013724","DOI":"10.1203\/00006450-199604000-00025"},{"key":"2021120819313445800_R40","doi-asserted-by":"crossref","unstructured":"Berry DD, Pramanik AK, Philips JB III, et al. Comparison of the effect of three doses of a synthetic surfactant on the alveolar-arterial oxygen gradient in infants weighing \u22651250 grams with respiratory distress syndrome: American Colfosceril Neonatal Study Group II. J Pediatr.\u20081994;124:294\u2013301","DOI":"10.1016\/S0022-3476(94)70323-X"},{"key":"2021120819313445800_R41","doi-asserted-by":"crossref","unstructured":"Hall SB, Venkitaraman AR, Whitsett JA, Holm BA, Notter RH. Importance of hydrophobic apoproteins as constituents of clinical exogenous surfactants. Am Rev Respir Dis.\u20081992;145:24\u201330","DOI":"10.1164\/ajrccm\/145.1.24"},{"key":"2021120819313445800_R42","doi-asserted-by":"crossref","unstructured":"Ainsworth SB, Beresford MW, Milligan DW, et al. Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25\u201329 weeks' gestation: a randomized trial. Lancet.\u20082000;355:1387\u20131392","DOI":"10.1016\/S0140-6736(00)02136-X"},{"key":"2021120819313445800_R43","doi-asserted-by":"crossref","unstructured":"van Eijk M, De Haas CG, Haagsman HP. Quantitative analysis of pulmonary surfactant proteins B and C. Anal Biochem.\u20081995;232:231\u2013237","DOI":"10.1006\/abio.1995.0012"},{"key":"2021120819313445800_R44","doi-asserted-by":"crossref","unstructured":"Mizuno K, Ikegami M, Chen CM, Ueda T, Jobe AH. Surfactant protein-B supplementation improves in vivo function of a modified natural surfactant. Pediatr Res.\u20081995;37:271\u2013276","DOI":"10.1203\/00006450-199503000-00004"},{"key":"2021120819313445800_R45","doi-asserted-by":"crossref","unstructured":"Seeger W, Grube C, Gunther A, Schmidt R. Surfactant inhibition by plasma proteins: differential sensitivity of various surfactant preparations. Eur Respir J.\u20081993;6:971\u2013977","DOI":"10.1183\/09031936.93.06070971"},{"key":"2021120819313445800_R46","doi-asserted-by":"crossref","unstructured":"Romero EJ, Moya FR, Tuvim MJ, Alcorn JL. Interaction of an artificial surfactant in human pulmonary epithelial cells. Pediatr Pulmonol.\u20082005;39:167\u2013177","DOI":"10.1002\/ppul.20166"},{"key":"2021120819313445800_R47","doi-asserted-by":"crossref","unstructured":"Sinha S, Lacaze-Masmonteil T, Valls i Soler A, et al. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa in very premature infants at high risk for respiratory distress syndrome. Pediatrics.\u20082005;115:1030\u20131038","DOI":"10.1542\/peds.2004-2231"},{"key":"2021120819313445800_R48","doi-asserted-by":"crossref","unstructured":"Kukkonen AK, Virtanen M, Jarvenpaa AL, Pokela ML, Ikonen S, Fellman V. Randomized trial comparing natural and synthetic surfactant: increased infection rate after natural surfactant?Acta Paediatr.\u20082000;89:510\u2013512","DOI":"10.1080\/080352500750027754"},{"key":"2021120819313445800_R49","doi-asserted-by":"crossref","unstructured":"Kaiser JR, Gauss CH, Williams DK. Surfactant administration acutely affects cerebral and systemic hemodynamics and gas exchange in very-low-birth-weight infants. J Pediatr.\u20082004;144:809\u2013814","DOI":"10.1016\/j.jpeds.2004.03.022"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/115\/4\/1018\/1176478\/zpe00405001018.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/115\/4\/1018\/1176478\/zpe00405001018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T19:56:09Z","timestamp":1683057369000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/115\/4\/1018\/67666\/A-Multicenter-Randomized-Masked-Comparison-Trial"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4,1]]},"references-count":49,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2005,4,1]]},"published-print":{"date-parts":[[2005,4,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2004-2183","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,4,1]]}}}